Daxor Stock Forecast, Price & News

-0.77 (-5.79 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume400 shs
Average Volume14,314 shs
Market Capitalization$48.77 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DXR News and Ratings via Email

Sign-up to receive the latest news and ratings for Daxor and its competitors with MarketBeat's FREE daily newsletter.

Daxor logo

About Daxor

Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.72 out of 5 stars

Medical Sector

260th out of 2,099 stocks

Surgical & Medical Instruments Industry

26th out of 174 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Daxor (NYSEAMERICAN:DXR) Frequently Asked Questions

Is Daxor a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daxor in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Daxor stock.
View analyst ratings for Daxor
or view top-rated stocks.

What stocks does MarketBeat like better than Daxor?

Wall Street analysts have given Daxor a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Daxor wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Daxor?

Daxor saw a increase in short interest during the month of May. As of May 14th, there was short interest totaling 23,500 shares, an increase of 46.9% from the April 29th total of 16,000 shares. Based on an average daily trading volume, of 9,900 shares, the short-interest ratio is presently 2.4 days. Currently, 2.5% of the company's stock are sold short.
View Daxor's Short Interest

How has Daxor's stock price been impacted by Coronavirus (COVID-19)?

Daxor's stock was trading at $9.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DXR shares have increased by 27.8% and is now trading at $12.54.
View which stocks have been most impacted by COVID-19

What price target have analysts set for DXR?

2 analysts have issued 12-month target prices for Daxor's shares. Their forecasts range from $21.00 to $22.00. On average, they expect Daxor's share price to reach $21.50 in the next twelve months. This suggests a possible upside of 71.5% from the stock's current price.
View analysts' price targets for Daxor
or view top-rated stocks among Wall Street analysts.

Who are Daxor's key executives?

Daxor's management team includes the following people:
  • Mr. Michael Richard Feldschuh, Chairman, Pres & CEO (Age 52, Pay $100k)
  • Mr. Jonathan Adam Feldschuh, Chief Scientific Officer & Director (Age 56, Pay $127.92k)
  • Mr. Robert J. Michel M.B.A., CPA, CPA, CFO, Chief Compliance Officer & Corp. Sec. (Age 64)
  • Ms. Kathryn A. Kornafel, VP of Marketing & Commercial Devel.
  • Mr. Guido Manzo, VP of Sales

Who are some of Daxor's key competitors?

What other stocks do shareholders of Daxor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daxor investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Pfizer (PFE), ContraFect (CFRX), Dynavax Technologies (DVAX), iBio (IBIO), (MRNA), Micron Technology (MU) and (SNY).

What is Daxor's stock symbol?

Daxor trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "DXR."

How do I buy shares of Daxor?

Shares of DXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Daxor's stock price today?

One share of DXR stock can currently be purchased for approximately $12.54.

How much money does Daxor make?

Daxor has a market capitalization of $48.77 million.

What is Daxor's official website?

The official website for Daxor is www.daxor.com.

Where are Daxor's headquarters?

Daxor is headquartered at 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States.

How can I contact Daxor?

Daxor's mailing address is 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States. The company can be reached via phone at +1-212-3308500 or via email at [email protected]

This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.